Nader Rahimi (born December 22, 1963) is a Molecular Biologist and is currently an Associate Professor at the Department of Pathology and Laboratory Medicine at Boston University.

[2] He completed his postdoctoral fellowship at Harvard Medical School in the fields of signal transduction and angiogenesis.

His notable works include demonstration of differential function of VEGFR-1 and VEGFR-2 in angiogenesis,[4] identification of lysine methylation as a novel mechanism of activation of VEGFR-2,[5] establishing protein ubiquitination as a major pathway modulating the angiogenic signaling of VEGFR-2.

[6][7][8][9] He is also responsible for the discovery of multiple cell surface receptors including, IGPR-1 (TMIGD2),[10][11][12][13] TMIGD1,[14][15] MINAR1,[16] and MINAR2.

[17] His work on COVID-19 resulted in the discovery of CD209L and CD209 as novel receptors [18][19] and vimentin as an attachment factor for SARS-CoV-2.